Therapeutic Drug Monitoring of Rituximab to Predict Early B-Cell Repopulation in Children With Inflammatory Diseases
Authors' conclusion
This proof-of-concept study demonstrates that rituximab serum concentration measurements can predict future drug concentrations that are associated with early B-cell repopulation.
Study context
- Population
- Children and adolescents receiving rituximab for AAV, neuroinflammatory disease or childhood-onset SLE40 samples
- Participants
- 10 children
- Outcome
- Accuracy of predicted vs measured future rituximab serum concentrations (absolute error)
Methodological detailspharmacokinetic prediction, exponential decay model
- Pharmacokinetic prediction
- Exponential decay model
Main finding
As reported in the abstract
Rituximab half-life, median (range 1.7-3.5)
2.7 weeks
Absolute error of predictions, median (IQR −0.02 to 0.26); slight overestimation
0.12 μg/mL
Time to minimum concentration for B-cell depletion (0.55 μg/mL), median (range 13.3-28.8)
22.2 weeks
Participants with B-cell repopulation, at concentrations ≤ 0.3 μg/mL
5
Further findings
- Participants with positive antidrug antibodies (half-life 1.8 weeks)
- 1
Original publication
Therapeutic Drug Monitoring of Rituximab to Predict Early B-Cell Repopulation in Children With Inflammatory Diseases. J Rheumatol. Published 1 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →